Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market, Size, Share, Analysis Report & Forecast to 2026

Asia-Pacific STD diagnostics market is growing at a CAGR of around 9.4% during the forecast period. The region has the second-highest HIV prevalence. Major countries such as China, India and Indonesia account for around three-quarters of the total number of people living with HIV. There is a huge variation across the region in terms of the incidence of HIV and countries’ responses to the diagnosis and treatment. However, investments by countries with HIV diagnosis and treatment in the region have doubled over the last decade.

Free Sample Copy @ https://www.omrglobal.com/request-sample/asia-pacific-sexually-transmitted-disease-market

There is a significant increase in the incidence and prevalence of genital herpes and genital warts in the region. Gonorrhea is the most dominant STD in the region, with a high incidence of chromosomally-mediated resistant and penicillinase-producing strains comprising around 35%-50% of isolates. Clinical treatment failures due to spectinomycin-resistant gonococci are increasing in the APAC region. Uncontrolled antibiotic sales are responsible for these resistant strains. Further, STDs such as syphilis incidence was declined in 1950, however, it has re-emerged in the APAC region. The incidence of Cancroid is decreasing, while herpes is making up a greater share in the ulcer disease. The high incidence of STDs in this area is an indication of future trends of HIV/AIDS in the APAC region. The Asia-Pacific STD diagnostics market is strongly fueled by the rapid spread of human papilloma virus infection among the female population.

A Full Report of Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market is Available at:
https://www.omrglobal.com/industry-reports/asia-pacific-sexually-transmitted-disease-market

In addition, supportive government initiatives and prevention programs are impacting the growth of Asia-Pacific STD diagnostics market as it has succeeded in reducing new HIV infections across the region. However, late diagnosis remains a key area of concern. Many countries in APAC have disciplinary and stigmatizing laws in place, which prevent members of key affected individuals from accessing services and work to support HIV stigma. According to UNAID (Joint United Nations Program on HIV/AIDS), in 2018, there were approximately 310,000 new infections in the region. The progress in reducing new infections has slowed in recent years and new HIV infections are on the rise in some countries of the region.

Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market – Segmentation
by Disease Type
Chlamydia
Syphilis
Gonorrhea
Herpes Simplex Virus (HSV)
Human Papilloma Virus (HPV)
Human Immunodeficiency Virus (HIV)
Others
by Product
Laboratory Testing Devices
Point-of-Care (POC) Testing Devices
by End-user
Hospitals and Clinics
Diagnostic Centers
Homecare

Asia-Pacific Sexually Transmitted Diseases (STD) Diagnostics Market – Segmentation by Region
China
Japan
India
Rest of Asia-Pacific

Company Profiles
Abbott Laboratories, Inc.
AbbVie Inc.
Becton, Dickinson and Co.
Biocartis NV
Bio-Rad Laboratories, Inc.
Danaher Corp.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Merck KGaA
Thermo Fisher Scientific, Inc.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-sexually-transmitted-disease-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

 

(This release has been published on Global Market Post.
Global Market Post is not responsible for any content included in this release.)

Leave a Reply

Your email address will not be published. Required fields are marked *